Long-term Observational Study of Patients Treated With Inaticabtagene Autoleucel Injection

Recruiting now

Conditions studied: B-cell Tumors

In brief

This clinical trial adopts an observational research method to conduct annual follow-up and monitoring of patients receiving treatment with Inaticabtagene Autoleucel Injection after its commercialization, in order to evaluate the delayed adverse events of Inaticabtagene Autoleucel Injection.

Key facts

Study ID

NCT06461351

Run by

Juventas Cell Therapy Ltd.

People needed

1000

Starts

2024-03-30

Expected to finish

2040-03-30

Last updated by the study team

2025-08-07

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Agree to sign an informed consent form for long-term follow-up studies.
• Registered clinical trial patients with different indications for this product who have received at least one infusion of Inaticabtagene Autoleucel Injection in the past, as well as post market commercialized patients.

You may not qualify if…

• None.

Where it is running

• Institute of Hematology & Blood Diseases Hospital — Tianjin, Tianjin Municipality, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.